Controlled Porosity Solubility Modulated Osmotic Pump Tablets of Gliclazide

被引:16
作者
Banerjee, Arti [1 ]
Verma, P. R. P. [2 ]
Gore, Subhash [1 ]
机构
[1] Mylan Labs Ltd, FDS, R&D Ctr, Hyderabad 502325, Andhra Pradesh, India
[2] Birla Inst Technol, Ranchi, Bihar, India
关键词
convolution approach; gliclazide; hot melt extrusion (HME); hydroxypropyl cellulose; solid dispersion; MECHANICAL DESTRUCTIVE FORCE; SOLID DISPERSIONS; MELT EXTRUSION; DRUG-DELIVERY; DISSOLUTION; ENHANCEMENT; BIOEQUIVALENCE; ETHYLCELLULOSE; PERFORMANCE; POLYMERS;
D O I
10.1208/s12249-014-0246-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A system that can deliver drug at a controlled rate is very important for the treatment of various chronic diseases such as diabetes, asthma, and heart disease. Poorly water-soluble drug with pH-dependent solubility such as gliclazide (GLZ) offers challenges in the controlled-release formulation because of low dissolution rate and poor bioavailability. Solid dispersion (SD) of GLZ consisted of hydroxypropyl cellulose (HPC-SSL) as a polymeric solubilizer was manufactured by hot melt extrusion (HME) technology. Then, controlled porosity osmotic pump (CPOP) tablet of gliclazide was designed to deliver drug in a controlled manner up to 16 h. The developed formulation was optimized for type and level of pore former and coating weight gain. The optimized formulation was found to exhibit zero order kinetics independent of pH and agitation speed but depends on osmotic pressure of dissolution media indicated that mechanism of drug release was osmotic pressure. The in vivo performance prediction of developed formulation using convolution approach revealed that the developed formulation was superior to the existing marketed extended-release formulation in terms of attaining steady state plasma levels and indicated adequate exposure in translating hypoglycemic response. The prototype solubilization method combined with controlled porosity osmotic pump based technique could provide a unique way to increase dissolution rate and bioavailability of many poorly water-soluble, narrow therapeutic index drugs used in diabetes, cardiovascular diseases, etc.
引用
收藏
页码:554 / 568
页数:15
相关论文
共 55 条
[1]  
Aggarwal S, 2002, PHARMAZIE, V57, P191
[2]   USE OF MODIFIED ETHYLCELLULOSE LATTICES FOR MICROPOROUS COATING OF OSMOTIC TABLETS [J].
APPEL, LE ;
ZENTNER, GM .
PHARMACEUTICAL RESEARCH, 1991, 8 (05) :600-604
[3]   Enhancement of dissolution rate of gliclazide using solid dispersions with polyethylene glycol 6000 [J].
Biswal, S. ;
Sahoo, J. ;
Murthy, P. N. ;
Giradkar, R. P. ;
Avari, J. G. .
AAPS PHARMSCITECH, 2008, 9 (02) :563-570
[4]   Physicochemical Properties of Solid Dispersions of Gliclazide in Polyvinylpyrrolidone K90 [J].
Biswal, S. ;
Sahoo, J. ;
Murthy, P. N. .
AAPS PHARMSCITECH, 2009, 10 (02) :329-334
[5]  
Breitenbach J., 2008, EXACT, P8
[6]  
Campbell D B., 1980, Academic Press and the Royal Society of Medicine, P71
[7]   Gliclazide and bedtime insulin are more efficient than insulin alone for type 2 diabetic patients with sulfonylurea secondary failure [J].
Chazan, ACS ;
Gomes, MB .
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2001, 34 (01) :49-56
[8]  
Chokshi R., 2004, IRAN J PHARM RES IJP, V3, DOI DOI 10.1211/jpp/61.08.0001
[9]   Modeling and comparison of dissolution profiles [J].
Costa, P ;
Manuel, J ;
Lobo, S .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 13 (02) :123-133
[10]   Pharmaceutical applications of hot-melt extrusion: Part I [J].
Crowley, Michael M. ;
Zhang, Feng ;
Repka, Michael A. ;
Thumma, Sridhar ;
Upadhye, Sampada B. ;
Battu, Sunil Kumar ;
McGinity, James W. ;
Martin, Charles .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2007, 33 (09) :909-926